Association between XRCC1 rs1799782 polymorphism and thyroid cancer risk: a meta-analysis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

WU Yayun , CAO Zhimin ,  ZHANG Kai , LIU Rubin , ZHANG Qiang , HAN Fei

Department of Head and Neck Surgery, Fuyang Cancer Hospital, Fuyang, Anhui 236000, P. R. China;

Corresponding author：

ZHANG Kai, Email: 825269275@qq.com

Keywords：

thyroid cancer; X-ray cross complementary repair gene-1; rs1799782 locus; polymorphism; meta-analysis

DOI：

10.7507/1007-9424.202103102

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the association between single nucleotide polymorphism (SNP) in the X-ray cross complementary repair gene-1 (XRCC1) rs1799782 locus and thyroid cancer.Methods Studies investigating the association between SNP in the XRCC1 gene and thyroid cancer susceptibility were retrieved from the PubMed, Embase, Web of Science, CNKI (Chinese National Knowledge Infrastructure), Wanfang, and CBM (China Biology Medicine) databases (published date up to February 15, 2021). Eligible studies were screened according to inclusion/exclusion criteria and principles of quality evaluation. Meta-analysis was performed using Stata 14.0 software. Odds ratios with their corresponding 95% confidence intervals (95%CI) were pooled to assess the association between SNP in the XRCC1 gene rs1799782 locus and thyroid cancer susceptibility.Results Twelve articles were eligible for this meta-analysis. Meta-analysis results were shown as follows: No significant association was found between XRCC1 rs1799782 polymorphism and thyroid cancer in overall population [Dominant model: CT+TT vs CC, OR=1.07, 95%CI (0.84, 1.36). Recessive model: TT vs CT+CC, OR=1.48, 95%CI (0.95, 2.31). Allelic model: T vs C, OR=1.15, 95%CI (0.93, 1.43). Codominant model: TT vs CC: OR=1.44, 95%CI (0.83, 2.53); CT vs CC, OR=1.02, 95%CI (0.82, 1.28); TT vs CT, OR=1.40, 95%CI (0.98, 1.99)]. rs1799782 polymorphism was significantly associated with the risk of thyroid cancer in Chinese population [Dominant model: CT+TT vs CC, OR=1.38, 95%CI (1.11, 1.71). Recessive model : TT vs CT+CC, OR=1.97, 95%CI (1.55, 2.50); Allelic model: T vs C, OR=1.40, 95%CI (1.16, 1.68). Codominant model: TT vs CC, OR=2.12, 95%CI (1.66, 2.71); CT vs CC, OR=1.26, 95%CI (1.09, 1.47); TT vs CT, OR=1.70, 95%CI (1.31, 2.21)]. rs1799782 polymorphism was significantly associated with the risk of thyroid cancer in Asian population [Dominant model: CT+TT vs CC, OR=0.64, 95%CI (0.49, 0.83). Codominant model: TT vs CC: OR=0.50, 95%CI (0.33, 0.74); CT vs CC, OR=0.65, 95%CI (0.49, 0.86)].Conclusions There is no significant correlation between XRCC1 rs1799782 polymorphism and the risk of thyroid cancer in general population. The XRCC1 rs1799782 polymorphism may be associated with an increased thyroid cancer risk among Chinese, and a tendency for decreased thyroid cancer risk among Asians (Chinese excluded). The XRCC1 rs1799782 polymorphism is not associated with thyroid cancer susceptibility among Caucasians under all genetic models.

Citation： WU Yayun, CAO Zhimin, ZHANG Kai, LIU Rubin, ZHANG Qiang, HAN Fei. Association between XRCC1 rs1799782 polymorphism and thyroid cancer risk: a meta-analysis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(11): 1477-1485. doi: 10.7507/1007-9424.202103102 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	Wang W, Chang J, Jia B, et al. The blood biomarkers of thyroid cancer. Cancer Manag Res, 2020, 12: 5431-5438.
3.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
4.	Pitoia F, Smulever A. Active surveillance in low risk papillary thyroid carcinoma. World J Clin Oncol, 2020, 11(6): 320-336.
5.	Houten R, Fleeman N, Kotas E, et al. A systematic review of health state utility values for thyroid cancer. Qual Life Res, 2021, 30(3): 675-702.
6.	Zhao JZ, Tan XR, Zhao M, et al. Association between the X-ray repair cross-complementing group 1 Arg194Trp polymorphism and thyroid carcinoma susceptibility: A meta-analysis. Genet Mol Res, 2016, 15(3): gmr. 15037793.
7.	Chou WC, Wang HC, Wong FH, et al. Chk2-dependent phosphorylation of XRCC1 in the DNA damage response promotes base excision repair. EMBO J, 2008, 27(23): 3140-3150.
8.	Caldecott KW. XRCC1 protein; Form and function. DNA Repair (Amst), 2019, 81: 102664.
9.	Du Y, Han LY, Li DD, et al. Associations between XRCC1 Arg399Gln, Arg194Trp, and Arg280His polymorphisms and risk of differentiated thyroid carcinoma: a meta-analysis. Asian Pac J Cancer Prev, 2013, 14(9): 5483-5487.
10.	Hu Z, Hu X, Long J, et al. XRCC1 polymorphisms and differentiated thyroid carcinoma risk: a meta-analysis. Gene, 2013, 528(2): 67-73.
11.	Li C, Xiang X, Zhou Y. No association between XRCC1 genetic polymorphisms and differentiated thyroid carcinoma risk: a meta-analysis. Mol Biol Rep, 2014, 41(11): 7613-7621.
12.	Liu SY, Xue W. XRCC1 Arg194Trp polymorphism and thyroid cancer. J Endocrinol Invest, 2020, 43(6): 749-753.
13.	Adampourezare M, Hosseinpourefeizi MA, Pouladi N, et al. Association of Arg194Trp and Arg399Gln polymorphisms of XRCC1 gene and risk of differentiated thyroid carcinoma in Iranian-Azeri patients. Int J Cancer Manag, 2017, 10(7): e5790.
14.	朱虔兮, 边建超, 沈强, 等. X线交错互补修复基因1多态与乳头状甲状腺癌的遗传易感性. 中华流行病学杂志, 2004, 25(8): 702-705.
15.	Chiang FY, Wu CW, Hsiao PJ, et al. Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma. Clin Cancer Res, 2008, 14(18): 5919-5924.
16.	Ho T, Li G, Lu J, et al. Association of XRCC1 polymorphisms and risk of differentiated thyroid carcinoma: a case-control analysis. Thyroid, 2009, 19(2): 129-135.
17.	Sigurdson AJ, Land CE, Bhatti P, et al. Thyroid nodules, polymorphic variants in DNA repair and RET-related genes, and interaction with ionizing radiation exposure from nuclear tests in Kazakhstan. Radiat Res, 2009, 171(1): 77-88.
18.	Ryu RA, Tae K, Min HJ, et al. XRCC1 polymorphisms and risk of papillary thyroid carcinoma in a Korean sample. J Korean Med Sci, 2011, 26(8): 991-995.
19.	Fard-Esfahani P, Fard-Esfahani A, Fayaz S, et al. Association of Arg194Trp, Arg280His and Arg399Gln polymorphisms in X-ray repair cross-complementing group 1 gene and risk of differentiated thyroid carcinoma in Iran. Iran Biomed J, 2011, 15(3): 73-78.
20.	Santos LS, Branco SC, Silva SN, et al. Polymorphisms in base excision repair genes and thyroid cancer risk. Oncol Rep, 2012, 28(5): 1859-1868.
21.	Wang X, Zhang K, Liu X, et al. Association between XRCC1 and XRCC3 gene polymorphisms and risk of thyroid cancer. Int J Clin Exp Pathol, 2015, 8(3): 3160-3167.
22.	Halkova T, Dvorakova S, Sykorova V, et al. Polymorphisms in selected DNA repair genes and cell cycle regulating genes involved in the risk of papillary thyroid carcinoma. Cancer Biomark, 2016, 17(1): 97-106.
23.	Yan L, Li Q, Li X, et al. Association studies between XRCC1, XRCC2, XRCC3 polymorphisms and differentiated thyroid carcinoma. Cell Physiol Biochem, 2016, 38(3): 1075-1084.
24.	Bashir K, Sarwar R, Fatima S, et al. Haplotype analysis of XRCC1 gene polymorphisms and the risk of thyroid carcinoma. J BUON, 2018, 23(1): 234-243.
25.	Zhu J, Qi P, Li Z. Interaction between XRCC1 gene polymorphisms and obesity on susceptibility to papillary thyroid cancer in Chinese Han Population. Cell Physiol Biochem, 2018, 49(2): 638-644.
26.	Whitehouse CJ, Taylor RM, Thistlethwaite A, et al. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell, 2001, 104(1): 107-117.
27.	Nanda SS, Gandhi AK, Rastogi M, et al. Evaluation of XRCC1 gene polymorphism as a biomarker in head and neck cancer patients undergoing chemoradiation therapy. Int J Radiat Oncol Biol Phys, 2018, 101(3): 593-601.
28.	Devi KR, Ahmed J, Narain K, et al. DNA repair mechanism gene, XRCC1A (Arg194Trp) but not XRCC3 (Thr241Met) polymorphism increased the risk of breast cancer in premenopausal females: A case-control study in northeastern region of India. Technol Cancer Res Treat, 2017, 16(6): 1150-1159.
29.	Al Mutairi FM, Alanazi M, Shalaby M, et al. Association of XRCC1 gene polymorphisms with breast cancer susceptibility in Saudi patients. Asian Pac J Cancer Prev, 2013, 14(6): 3809-3813.
30.	Du Y, He Y, Mei Z, et al. Association between genetic polymorphisms in XPD and XRCC1 genes and risks of non-small cell lung cancer in East Chinese Han population. Clin Respir J, 2016, 10(3): 311-317.
31.	Wang H, Liu Z. Polymorphism of DNA repair gene xrcc1 and lung cancer risk. Cell Biochem Biophys, 2014, 70(3): 1881-1886.
32.	Jafari Nedooshan J, Forat Yazdi M, Neamatzadeh H, et al. Genetic association of XRCC1 gene rs1799782, rs25487 and rs25489 polymorphisms with risk of thyroid cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 2017, 18(1): 263-270.
33.	Xing D, Qi J, Miao X, et al. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer, 2002, 100(5): 600-605.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. Wang W, Chang J, Jia B, et al. The blood biomarkers of thyroid cancer. Cancer Manag Res, 2020, 12: 5431-5438.
3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
4. Pitoia F, Smulever A. Active surveillance in low risk papillary thyroid carcinoma. World J Clin Oncol, 2020, 11(6): 320-336.
5. Houten R, Fleeman N, Kotas E, et al. A systematic review of health state utility values for thyroid cancer. Qual Life Res, 2021, 30(3): 675-702.
6. Zhao JZ, Tan XR, Zhao M, et al. Association between the X-ray repair cross-complementing group 1 Arg194Trp polymorphism and thyroid carcinoma susceptibility: A meta-analysis. Genet Mol Res, 2016, 15(3): gmr. 15037793.
7. Chou WC, Wang HC, Wong FH, et al. Chk2-dependent phosphorylation of XRCC1 in the DNA damage response promotes base excision repair. EMBO J, 2008, 27(23): 3140-3150.
8. Caldecott KW. XRCC1 protein; Form and function. DNA Repair (Amst), 2019, 81: 102664.
9. Du Y, Han LY, Li DD, et al. Associations between XRCC1 Arg399Gln, Arg194Trp, and Arg280His polymorphisms and risk of differentiated thyroid carcinoma: a meta-analysis. Asian Pac J Cancer Prev, 2013, 14(9): 5483-5487.
10. Hu Z, Hu X, Long J, et al. XRCC1 polymorphisms and differentiated thyroid carcinoma risk: a meta-analysis. Gene, 2013, 528(2): 67-73.
11. Li C, Xiang X, Zhou Y. No association between XRCC1 genetic polymorphisms and differentiated thyroid carcinoma risk: a meta-analysis. Mol Biol Rep, 2014, 41(11): 7613-7621.
12. Liu SY, Xue W. XRCC1 Arg194Trp polymorphism and thyroid cancer. J Endocrinol Invest, 2020, 43(6): 749-753.
13. Adampourezare M, Hosseinpourefeizi MA, Pouladi N, et al. Association of Arg194Trp and Arg399Gln polymorphisms of XRCC1 gene and risk of differentiated thyroid carcinoma in Iranian-Azeri patients. Int J Cancer Manag, 2017, 10(7): e5790.
14. 朱虔兮, 边建超, 沈强, 等. X线交错互补修复基因1多态与乳头状甲状腺癌的遗传易感性. 中华流行病学杂志, 2004, 25(8): 702-705.
15. Chiang FY, Wu CW, Hsiao PJ, et al. Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma. Clin Cancer Res, 2008, 14(18): 5919-5924.
16. Ho T, Li G, Lu J, et al. Association of XRCC1 polymorphisms and risk of differentiated thyroid carcinoma: a case-control analysis. Thyroid, 2009, 19(2): 129-135.
17. Sigurdson AJ, Land CE, Bhatti P, et al. Thyroid nodules, polymorphic variants in DNA repair and RET-related genes, and interaction with ionizing radiation exposure from nuclear tests in Kazakhstan. Radiat Res, 2009, 171(1): 77-88.
18. Ryu RA, Tae K, Min HJ, et al. XRCC1 polymorphisms and risk of papillary thyroid carcinoma in a Korean sample. J Korean Med Sci, 2011, 26(8): 991-995.
19. Fard-Esfahani P, Fard-Esfahani A, Fayaz S, et al. Association of Arg194Trp, Arg280His and Arg399Gln polymorphisms in X-ray repair cross-complementing group 1 gene and risk of differentiated thyroid carcinoma in Iran. Iran Biomed J, 2011, 15(3): 73-78.
20. Santos LS, Branco SC, Silva SN, et al. Polymorphisms in base excision repair genes and thyroid cancer risk. Oncol Rep, 2012, 28(5): 1859-1868.
21. Wang X, Zhang K, Liu X, et al. Association between XRCC1 and XRCC3 gene polymorphisms and risk of thyroid cancer. Int J Clin Exp Pathol, 2015, 8(3): 3160-3167.
22. Halkova T, Dvorakova S, Sykorova V, et al. Polymorphisms in selected DNA repair genes and cell cycle regulating genes involved in the risk of papillary thyroid carcinoma. Cancer Biomark, 2016, 17(1): 97-106.
23. Yan L, Li Q, Li X, et al. Association studies between XRCC1, XRCC2, XRCC3 polymorphisms and differentiated thyroid carcinoma. Cell Physiol Biochem, 2016, 38(3): 1075-1084.
24. Bashir K, Sarwar R, Fatima S, et al. Haplotype analysis of XRCC1 gene polymorphisms and the risk of thyroid carcinoma. J BUON, 2018, 23(1): 234-243.
25. Zhu J, Qi P, Li Z. Interaction between XRCC1 gene polymorphisms and obesity on susceptibility to papillary thyroid cancer in Chinese Han Population. Cell Physiol Biochem, 2018, 49(2): 638-644.
26. Whitehouse CJ, Taylor RM, Thistlethwaite A, et al. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell, 2001, 104(1): 107-117.
27. Nanda SS, Gandhi AK, Rastogi M, et al. Evaluation of XRCC1 gene polymorphism as a biomarker in head and neck cancer patients undergoing chemoradiation therapy. Int J Radiat Oncol Biol Phys, 2018, 101(3): 593-601.
28. Devi KR, Ahmed J, Narain K, et al. DNA repair mechanism gene, XRCC1A (Arg194Trp) but not XRCC3 (Thr241Met) polymorphism increased the risk of breast cancer in premenopausal females: A case-control study in northeastern region of India. Technol Cancer Res Treat, 2017, 16(6): 1150-1159.
29. Al Mutairi FM, Alanazi M, Shalaby M, et al. Association of XRCC1 gene polymorphisms with breast cancer susceptibility in Saudi patients. Asian Pac J Cancer Prev, 2013, 14(6): 3809-3813.
30. Du Y, He Y, Mei Z, et al. Association between genetic polymorphisms in XPD and XRCC1 genes and risks of non-small cell lung cancer in East Chinese Han population. Clin Respir J, 2016, 10(3): 311-317.
31. Wang H, Liu Z. Polymorphism of DNA repair gene xrcc1 and lung cancer risk. Cell Biochem Biophys, 2014, 70(3): 1881-1886.
32. Jafari Nedooshan J, Forat Yazdi M, Neamatzadeh H, et al. Genetic association of XRCC1 gene rs1799782, rs25487 and rs25489 polymorphisms with risk of thyroid cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 2017, 18(1): 263-270.
33. Xing D, Qi J, Miao X, et al. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer, 2002, 100(5): 600-605.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Association between XRCC1 rs1799782 polymorphism and thyroid cancer risk: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content